Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21134598 | 1.00 | SLC6A4 (0.33) | SLC6A4SLC6A3KDM4EPKMESR2 | |
| SCHEMBL21134592 | 1.00 | SLC6A4 (0.33) | SLC6A4SLC6A3KDM4EPKMESR2 | |
| SCHEMBL8074193 | 0.86 | OPRM1 (0.39) | KDM4EPKMHSD17B3 | |
| SCHEMBL13213903 | 0.83 | OPRM1 (0.42) | HSD17B3 | |
| SCHEMBL9815873 | 0.81 | SHBG (0.33) | SLC6A4SLC6A3ESR2HSD17B3 | |
| SCHEMBL3012888 | 0.80 | KDM4E (0.34) | KDM4EPKMESR2 | |
| SCHEMBL17835264 | 0.80 | KDM4E (0.34) | KDM4EPKMESR2 | |
| SCHEMBL17706160 | 0.80 | KDM4E (0.34) | KDM4EPKMESR2 | |
| SCHEMBL129415 | 0.79 | — | — | |
| SCHEMBL9840935 | 0.76 | ALDH1A1 (0.33) | SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253576-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| EP-1632483-B1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMA INC (US) | 2008-10-29 | — | — | EP | disclosed |
| US-6410748-B1 | Alicycli c group-containing monomer | KABUSHIKI KAISHA TOSHIBA (JP) | 2002-06-25 | — | — | US | disclosed |
| US-6291129-B1 | LIGHT SENSITIVE ELEMENT WITH UNSATURATED POLYMERS | KABUSHIKI KAISHA TOSHIBA (JP) | 2001-09-18 | — | — | US | disclosed |
| US-6004719-A | ACID-GENERATING LAYER OR PHASE COMPRISING A MIXTURE OF A SUPERACID PRECURSOR, A SENSITIZING DYE AND A SECONDARY ACID GENERATOR, AND A COLOR-CHANGE LAYER OR PHASE COMPRISING AN IMAGE DYE. | POLAROID CORPORATION (US) | 1999-12-21 | — | — | US | disclosed |
| EP-0757629-B1 | IMAGING MEDIUM AND PROCESS | POLAROID CORP (US) | 1999-01-20 | — | — | EP | disclosed |
| EP-0757628-B1 | PROCESS FOR FIXING AN IMAGE | POLAROID CORP (US) | 1998-12-02 | — | — | EP | disclosed |
| EP-0665960-B1 | IMAGING MEDIUM AND PROCESS | POLAROID CORP (US) | 1998-08-19 | — | — | EP | disclosed |
| US-5631118-A | MULTILAYER ELEMENT WITH ACID GENERATING LAYER, ACID PRECURSOR, SENSITIZING DYE, ACID GENERATOR AND COLOR CHANGING LAYER | POLAROID CORPORATION (US) | 1997-05-20 | — | — | US | disclosed |
| EP-0757629-A1 | IMAGING MEDIUM AND PROCESS | POLAROID CORPORATION (US) | 1997-02-12 | — | — | EP | disclosed |
| WO-1995029068-A1 | IMAGING MEDIUM AND PROCESS | POLAROID CORPORATION (US) | 1995-11-02 | — | — | WO | disclosed |
| WO-1995029067-A1 | PROCESS FOR FIXING AN IMAGE | POLAROID CORPORATION (US) | 1995-11-02 | — | — | WO | disclosed |
| US-5453345-A | Imaging medium | POLAROID CORPORATION (US) | 1995-09-26 | — | — | US | disclosed |
| US-5445917-A | Superacid precursor to catalyze thermal decomposition of secondary acid generator, such as squaric acid and oxalic acid derivatives; effecting color change in imaging process | POLAROID CORPORATION (US) | 1995-08-29 | — | — | US | disclosed |
| US-5441850-A | Exposing medium to actinic radiation in specified wavelength so sensitizing dye decomposes superacid precursor, heating to decompose secondary acid generator, mixing acid generating and color change layers to form image, providing base to restore | POLAROID CORPORATION (US) | 1995-08-15 | — | — | US | disclosed |
| EP-0665961-A1 | IMAGING MEDIUM AND PROCESS. | POLAROID CORP (US) | 1995-08-09 | — | — | EP | disclosed |
| EP-0665960-A1 | IMAGING MEDIUM AND PROCESS | POLAROID CORPORATION (US) | 1995-08-09 | — | — | EP | disclosed |
| US-5395736-A | Exposing superoxide precursor to actinic radiation, generating superacid, mixing with oxalic acid diester, heating | POLAROID CORPORATION (US) | 1995-03-07 | — | — | US | disclosed |
| WO-1994010606-A1 | IMAGING MEDIUM AND PROCESS | POLAROID CORPORATION (US) | 1994-05-11 | — | — | WO | disclosed |
| WO-1994010607-A1 | IMAGING MEDIUM AND PROCESS | POLAROID CORPORATION (US) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253576-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | FNTB, SLC11A2, TBCD | SLC6A4 3031/4885SLC6A3 1578/4885KDM4E 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.